Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Journal of Global Antimicrobial Resistance Year : 2023

Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales

1 CNRARA/Service de Microbiologie - Centre National de Référence Associé de la Résistance aux Antibiotiques [Hôpital Bicêtre AP-HP]
2 IMVA-HB - Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes
3 UBH : Unité de Bactériologie-Hygiène - Service de Microbiologie [Hôpital Bicêtre AP-HP]
4 Service de bactériologie-Virologie-Hygiène [Avicenne]
5 HIA Begin - Hôpital d'Instruction des Armées Begin [Saint-Mandé, France]
6 DYNAMICURE - Dynamique Microbienne associée aux Infections Urinaires et Respiratoires
7 CHI Créteil
8 Hôpital Foch [Suresnes]
9 CHU Henri Mondor [Créteil]
10 IGR - Institut Gustave Roussy
11 CHU Limoges
12 CIC1435 - Centre d'Investigation Clinique de Limoges
13 RESINFIT - Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques
14 Hôpitaux Universitaires Saint-Louis, Lariboisière, Fernand-Widal
15 IAI - Institut des Agents Infectieux [Lyon]
16 INCIT - Immunology and New Concepts in ImmunoTherapy
17 Service de bactériologie et hygiène hospitalière [Nantes]
18 Hôpital Necker - Enfants Malades [AP-HP]
19 Laboratoire de Bactériologie [CHU Nice]
20 CHU de Poitiers [La Milétrie] - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
21 CHU Reims - Hôpital universitaire Robert Debré [Reims]
22 Hôpital Robert Debré
23 P3CELL - Pathologies Pulmonaires et Plasticité Cellulaire - UMR-S 1250
24 Laboratoire de Bactériologie et Hygiène Hospitalière [Rennes]
25 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
26 BRM - ARN régulateurs bactériens et médecine
27 hpsj - Groupe Hospitalier Paris Saint-Joseph
28 MICALIS - MICrobiologie de l'ALImentation au Service de la Santé
29 Virulence bactérienne précoce : fonctions cellulaires et contrôle de l'infection aiguë et subaiguë
30 Plateau technique de microbiologie, Laboratoire de bactériologie
31 HIA - Hopital d'instruction des armées Sainte-Anne [Toulon]
32 Hôpital Bretonneau
33 Service de Biologie [CH Versailles]
34 Université Paris-Saclay
Nathalie Soismier
  • Function : Author
Eric Farfour
Vincent Fihman
Emmanuelle Bille
Nicolas Degand
Cécile Le Brun
Marlène Amara

Abstract

Objectives: Ceftolozane-tazobactam (C/T) proved its efficacy for the treatment of infections caused by non-carbapenemase producing Pseudomonas aeruginosa and Enterobacterales. Here, we aimed to provide susceptibility data on large series of Enterobacterales since the revision of EUCAST categorization breakpoints in 2020. Methods: First, C/T susceptibility was determined on characterized Enterobacterales resistant to 3rd generation cephalosporins (3GC) (ESBL production or different levels of AmpC overexpression) (n=213) and carbapenem resistant Enterobacterales (CRE) (n=259) including 170 carbapenemase producers (CPE). Then, 1,632 consecutive clinical Enterobacterales responsible for infection were prospectively collected in 23 French hospitals. C/T susceptibility was determined by Etest® (biomérieux) and broth microdilution (BMD) (Sensititre™, Thermo Scientific) to perform method comparison. Results: Within the collection isolates, 88% of 3GC resistant strains were susceptible to C/T, with important variation depending on the resistance mechanism: 93% vs 13% susceptibility for CTX-M and SHV-ESBL producers, respectively. Only 20% of the CRE were susceptible to C/T. Among CPE, 80 % of OXA-48-like producers were susceptible to C/T, whereas all metallo-β-lactamase producers were resistant. The prospective study revealed that 95.6% of clinical isolates were susceptible to C/T. Method comparison performed on these 1,632 clinical isolates demonstrated 99 % of categorization agreement between MIC to C/T determined by Etest® compared to BMD (reference) and only 74% of essential agreement. Conclusion: Overall, C/T showed good activity against wild-type Enterobacterales, AmpC producers and ESBL-producing E. coli but is less active against ESBL-producing K. pneumoniae and CRE. Etest® led to an underestimation of the MICs in comparison to BMD.
Fichier principal
Vignette du fichier
1-s2.0-S2213716523000085-main (1).pdf (1.71 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

inserm-03962400 , version 1 (30-01-2023)

Identifiers

Cite

Agnès Jousset, Sandrine Bernabeu, Cécile Emeraud, Rémy Bonnin, Alexandra Lomont, et al.. Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales. Journal of Global Antimicrobial Resistance, 2023, 32, pp.78-84. ⟨10.1016/j.jgar.2023.01.003⟩. ⟨inserm-03962400⟩
255 View
93 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More